OTTMUSG00000010438 inhibitors are a class of chemical compounds that specifically target and block the activity of the protein encoded by the gene OTTMUSG00000010438, derived from mouse genomic research. Although the precise function of this gene may not yet be fully characterized, proteins in similar categories are typically involved in vital cellular processes such as signaling cascades, gene regulation, or structural roles within the cell. These inhibitors function by interfering with the normal activities of the protein, either by preventing it from binding to its molecular partners, disrupting its role in enzymatic functions, or hindering its involvement in intracellular signaling. By inhibiting this gene's activity, researchers can explore the molecular pathways that rely on OTTMUSG00000010438 for proper function and regulation.
Studying OTTMUSG00000010438 inhibitors provides valuable insights into how this protein contributes to the overall cellular environment. Inhibiting its function can lead to observable changes in processes such as protein synthesis, cellular metabolism, or signal transduction. These inhibitors offer researchers the ability to dissect the role of this protein in broader biological contexts, revealing how it interacts with other cellular pathways and networks. Moreover, such inhibitors can help clarify the protein's specific function in maintaining cellular homeostasis and stability, further enhancing our understanding of the molecular mechanisms behind essential cellular activities. Through this research, OTTMUSG00000010438 inhibitors become useful tools for investigating complex molecular interactions and how precise gene regulation impacts broader cellular behavior.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib, a tyrosine kinase inhibitor, may impact signaling pathways involved in cell differentiation which could indirectly influence PRAME like 14. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, could affect protein degradation pathways, potentially impacting PRAME like 14 function. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, may influence chromatin remodeling, potentially impacting PRAME like 14 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib, an EGFR inhibitor, could alter cell signaling pathways that indirectly affect PRAME like 14. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid, another histone deacetylase inhibitor, could influence gene expression pathways, potentially impacting PRAME like 14. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib, a dual tyrosine kinase inhibitor, could influence cell growth pathways, impacting PRAME like 14 indirectly. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, targeting multiple kinases, could impact angiogenesis and cell growth pathways, influencing PRAME like 14. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib, an EGFR inhibitor, could modify cell signaling pathways, indirectly affecting PRAME like 14. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide, affecting cytokine production and angiogenesis, could indirectly influence PRAME like 14 function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib, a CDK4/6 inhibitor, may affect cell cycle regulation, potentially impacting PRAME like 14. | ||||||